You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The company is targeting a 2021 US launch for the test, which uses a pair of protein markers to diagnose stroke and allow treatment to begin more quickly.
Prevencio said that the agreement with Microsoft involves sales of cardiac blood tests to hospitals, life science companies, and contract research organizations.
The score's developers also suggest that current guidelines for stroke prevention may not be sufficient for individuals at higher genomic risk for the condition.
Neurosurgeon Christopher Kellner is developing a test for aneurysm detection and leading an industry-funded effort to profile blood clots from stroke patients.
Within the "Big Three" conditions, misdiagnoses related to stroke, sepsis, and lung cancer accounted for the most high-severity diagnostic error cases.
The guidelines provide recommendations for what CYP2C9 variant alleles should be included in clinical pharmacogenomic tests assessing that gene.
Researchers reported that elevated high-sensitivity troponin I is strongly associated with increased risk of cardiovascular disease in some populations.
The firm is using a microarray-based platform as part of a laboratory-based test to diagnose different types of stroke from blood samples.
Galaxy has licensed IP from Proteome Sciences for the development of a test for the diagnosis and timing of stroke onset to help inform treatment decisions.
A new study suggests binding proteins that target glucose or asparagine can be used in combination with cytolysin A-based nanopores to electrically detect the metabolites.